Table 1.
HR HPV* -attributable fraction reported in the articles from the literature review by precancer and cancer site.
Table 2.
Number of registered outpatient and inpatient care health care events, number of HR HPV-attributable events, and average cost per patient presented in 2006 €.
Fig 1.
HR HPV-attributable fraction of outpatient and inpatient health care events by high-risk human papillomavirus-related disease and gender.
(a) Outpatient and inpatient health care events for both genders. (b). Outpatient and inpatient health care events by gender. (c). Outpatient and inpatient health care events by disease among males (d) Outpatient and inpatient health care events by disease among females.
Table 3.
Number of registered sick leave and early retirement days and HPV-attributable sick leave and early retirement days in 2006, presented in €1000.
Fig 2.
HR HPV-attributable fraction of morbidity (i.e., sick leave and early retirement days) by HPV-related disease and gender.
(a) Morbidity by gender. (b) Sick leave days for both genders. (c) Early retirement days for both genders. (d) Morbidity (sick leave and early retirement days) for both genders. (e) Sick leave days among males. (f) Early retirement days by disease among males. (g) Sick leave and early retirement days among males. (h) Sick leave days by disease among females. (i) Early retirement days by disease among females. (j) Morbidity by disease among females.
Table 4.
Cost of premature death due to HR HPV-attributable cancers (presented in €1000).
Fig 3.
Attributable fraction of total costs including both direct costs (i.e., inpatient care and outpatient care) and indirect costs (i.e., mortality, sick leave, and early retirement days) presented per HPV-related disease and gender.
(a) Attributable fraction of total cost per HPV related precancer and cancer type. (b) Attributable fraction of total cost of HPV related precancers and cancers per cost type; direct costs and indirect costs. (c) Attributable fraction of total cost of HPV related precancers and cancers per gender. (d) Attributable fraction of total cost per HPV related precancers and cancers for females. (e) Attributable fraction of total cost per HPV related precancers and cancers for males.
Table 5.
Total annual HR HPV-attributable costs in Sweden in 2006, presented in €1000.